SC
RYTM icon

Stephens Consulting’s Rhythm Pharmaceuticals RYTM Stock Holding History

Stephens Consulting’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$1.06K – 1842
2025
Q1 		$1.06K Buy
+20
New +$1.11K ﹤0.01% 621

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stephens Consulting's RYTM Position: Q2 2025 in Review

Stephens Consulting sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 20 shares — an estimated $1.06K sold.

Stephens Consulting first reported a position in RYTM in Q1 2025 and held it in 1 quarter. The position peaked at $1.06K in Q1 2025. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • Stephens Consulting reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 20 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $1.06K.
  • Stephens Consulting first reported a position in Rhythm Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Rhythm Pharmaceuticals position peaked at $1.06K in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.